TB-500
Thymosin Beta-4 Synthetic Analogue
TB-500 is a synthetic peptide that mirrors the active region of Thymosin Beta-4, a naturally occurring protein central to actin sequestration, cell migration, and systemic tissue repair. It is studied for wound healing, muscle recovery, anti-inflammatory effects, and cardiac regeneration.
Mechanism of Action
TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical step in wound healing and tissue regeneration.
Unlike BPC-157, TB-500 distributes systemically after injection. Research demonstrates it promotes angiogenesis (new blood vessel formation) across the body, not just locally. This systemic reach makes it particularly relevant for widespread injury or recovery protocols.
TB-500 also upregulates matrix metalloproteinases (MMPs) and reduces local inflammatory mediators, creating a tissue environment more permissive to remodelling. Cardiac research has found TB-4 promotes migration of epicardial progenitor cells following infarction.
Research Evidence
TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been conducted, providing some early human safety data that informs TB-500 extrapolation.
Thymosin Beta-4 Promotes Cardiac Progenitor Cell Migration After Infarction
TB4 reactivated quiescent epicardial cells post-infarct, promoting their migration into injured myocardium and differentiation into smooth muscle cells — establishing a role in cardiac regeneration.
Thymosin Beta-4 Improves Dermal Wound Healing in db/db Mice
Topical and systemic TB4 accelerated wound closure in diabetic mice by promoting angiogenesis, collagen deposition, and keratinocyte migration, with superior outcomes versus controls.
Typical Research Protocol
TB-500 is typically dosed in milligrams (not micrograms) due to its larger molecular weight. Loading protocols use higher initial frequency before transitioning to maintenance dosing.
Safety Profile
Reported Side Effects
- Injection site reaction
- Mild fatigue (transient)
- Headache
- Lethargy in first days
Contraindications
- Active cancer (angiogenic activity)
- Pregnancy
- Platelet disorders or anticoagulant use
- Known peptide allergy
Published Research
624 indexed PubMed papers reference TB-500. The 20 most recent are listed below.
-
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
PMID 42757290 Open on PubMed →
-
Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards.
PMID 42752426 Open on PubMed →
- Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
- Dysregulation of circulating damage-associated molecular patterns in diabetic foot syndrome.
- Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology.
- PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo.
- Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review.
- Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
-
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation.
PMID 42222211 Open on PubMed →
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
- Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.
- Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
- A revised model of nuclear actin import: Importin 9 competes with cofilin, profilin, and RanGTP for actin binding.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
- Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing.
- Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.
Common Research Stacks
Frequently Asked Questions
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 (TB4) is the naturally occurring 43-amino-acid protein produced in the thymus and platelets. TB-500 is a synthetic peptide containing the conserved active fragment of TB4 (residues 17–23: Ac-LKKTETQ). TB-500 is cheaper to produce and is thought to retain the key healing properties of the parent molecule, but native TB4 has broader biological activity.
How is TB-500 different from BPC-157?
BPC-157 acts predominantly at the local injection site and through systemic NO pathway modulation. TB-500 distributes systemically and works primarily through actin sequestration and progenitor cell recruitment. The two compounds have complementary rather than overlapping mechanisms, which is why they are commonly combined.
What is a typical TB-500 loading protocol?
A common research protocol uses a loading phase of 5–10 mg twice weekly for 4–6 weeks to establish tissue saturation, followed by a maintenance phase of 5 mg once weekly. Duration depends on the indication — acute injury protocols run 4–6 weeks total; chronic or systemic conditions may extend to 8–12 weeks.
Can TB-500 be used for hair regeneration?
TB-500 and native Thymosin Beta-4 have shown hair follicle-stimulating effects in animal models, promoting the transition from telogen (resting) to anagen (growth) phase through Wnt pathway activation. Some researchers report hair regrowth as an incidental finding during injury recovery protocols. It is not established as a primary hair loss treatment in humans.
How long does a reconstituted TB-500 vial last?
Reconstituted TB-500 in bacteriostatic water is stable for approximately 4 weeks refrigerated at 2–8°C. Do not freeze reconstituted peptide — freeze/thaw cycles degrade the structure. Lyophilised (powder) vials stored correctly are stable for 12–24 months. Always use a multi-dose vial within 4 weeks of first reconstitution.
Is TB-500 prohibited in sport?
Yes — TB-500 is prohibited under WADA's Prohibited List (category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics). It is banned both in-competition and out-of-competition. Athletes subject to anti-doping programmes risk sanctions for a positive test.
Key Research References
- Bock-Marquette I et al. (2004). Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration. Nature.
- Ehrlich HP et al. (1983). Thymosin beta-4: actin polymerisation inhibitor. Science.
- Kleinman HK, Sosne G. (2016). Thymosin β4 promotes wound repair. Vitam Horm.
Explore more Recovery research compounds
Browse Recovery →